EU expands scope of Imbruvica to include untreated CLL patients
Treatment naïve patients lived longer without disease progression with the Imbruvica-based regimen than those given a chemotherapy-based one
Read More
Tag: ibrutinib
Imbruvica bags EU expansion for two indications
The approval follows the Positive Opinion from the European Medicines Agency’s CHMP, and marks the fifth European approval in as many years.
Read More
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.
Read More
Imbruvica/Gazyva combo improves PFS in CLL patients
A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage clinical trial.
Read More
Final NHS nod for Janssen’s Imbruvica
Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell lymphoma (MCL), after cost regulators issued a final green light for the drug.
Read More
NICE recommends Imbruvica for some MCL patients
It is looking likely that a subgroup of patients with mantle cell lymphoma (MCL) will get routine access to Janssen’s Imbruvica on the NHS.
Read More
FDA green lights first treatment for chronic GvHD
The US Food and Drug Administration has expanded the scope of Johnson & Johnson/AbbVie’s Imbruvica to include the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments, marking the first therapy specifically approved for the condition in the US.
Read More
Scotland first UK nation to routinely offer HIV PrEP
Scotland will become the first UK nation to routinely offer HIV pre-exposure prophylaxis to all eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada alongside four other new therapies to be funded by the NHS.
Read More
AbbVie/Janssen’s Imbruvica filed for graft-versus-host-disease
US regulators have agreed to review AbbVie and Janssen’s Imbruvica for previously treated chronic graft-versus-host-disease (cGVHD), a severe, potentially life-threatening consequence of stem cell or bone marrow transplant.
Read More
CLL patients get routine NHS access to Janssen’s Imbruvica
Cost regulators for the NHS in England and Wales have now published final guidelines endorsing Janssen’s Imbruvica to treat some patients with chronic lymphocytic leukaemia (CLL).
Read More
Imbruvica gets US nod for marginal zone lymphoma
Janssen and AbbVie’s Imbruvica has been cleared by regulators in the US to treat certain patients with marginal zone lymphoma (MZL), a rare form of non-Hodgkin’s lymphoma.
Read More
Janssen drops price of Imbruvica to secure NICE nod
It is looking likely that Janssen’s Imbruvica will be available to treat some people with chronic lymphocytic leukaemia (CLL) routinely on the NHS, after cost regulators issued draft guidelines endorsing its use.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
